



## Evofem Biosciences to Present at Emerging Growth Conference

SAN DIEGO, April 14, 2025 /PRNewswire/ -- Evofem Biosciences, Inc., (OTCQB: EVFM) today announced that members of its management team will present at the upcoming Emerging Growth Conference as follows:

---

Date: Thursday, April 17, 2025

Time: 10:50 – 11:20 am ET (7:50 – 8:20 am PT)

Live webcast: <https://evofem.investorroom.com/EmergingGrowth2025> or [click here](#)

Following the presentation, the Company plans to open the floor for questions. Investors, analysts and investment advisors are encouraged to register early for the conference and to submit questions in advance to [Questions@EmergingGrowth.com](mailto:Questions@EmergingGrowth.com).

The webcast will be live and archived thereafter via EmergingGrowth.com and on the [Emerging Growth YouTube Channel](#). A link to the archive will be added to the [event landing page](#) on Evofem's investor relations website when available.

### About Evofem Biosciences

**Evofem** is commercializing innovative products to address unmet needs in women's sexual and reproductive health. The Company generates revenue from the sale of two FDA-approved products.

**PHEXXI® (lactic acid, citric acid, and potassium bitartrate)** is the first and only hormone-free, on-demand prescription contraceptive vaginal gel. It comes in a box of 12 pre-filled applicators and is applied 0-60 minutes before each act of sex.

**SOLOSEC® (secnidazole) 2g oral granules** is a next generation 5-nitroimidazole drug FDA-approved oral antibiotic for the treatment of two sexual health diseases: bacterial vaginosis (BV), a common vaginal infection, in females 12 years of age and older, and trichomoniasis, a common sexually transmitted infection (STI), in people 12 years of age and older. SOLOSEC provides a complete course of therapy in just one oral dose. Evofem's commercial team relaunched SOLOSEC in November 2024, and promotes the product alongside PHEXXI to OB/GYNs in the U.S.

To learn more, visit [evofem.com](https://evofem.com).

PHEXXI® and SOLOSEC® are registered trademarks of Evofem Biosciences, Inc.

## Forward-Looking Statements

This press release includes "forward-looking statements," within the meaning of the safe harbor for forward-looking statements provided by Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. You are cautioned not to place undue reliance on these forward-looking statements, which are current only as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Important factors that could cause actual results to differ materially from those discussed or implied in the forward-looking statements are disclosed in the Company's SEC filings, including its Annual Report on Form 10-K for the year ended December 31, 2024 filed with the SEC on March 24, 2025, and any subsequent filings. All forward-looking statements are expressly qualified in their entirety by such factors. The Company does not undertake any duty to update any forward-looking statement except as required by law.

## Contact

Amy Raskopf, Chief Business Development Officer

Evofem Biosciences, Inc.

[araskopf@evofem.com](mailto:araskopf@evofem.com)

(917) 673-5775

SOURCE Evofem Biosciences, Inc.